389 related articles for article (PubMed ID: 31409904)
1. Mitochondrial fission causes cisplatin resistance under hypoxic conditions via ROS in ovarian cancer cells.
Han Y; Kim B; Cho U; Park IS; Kim SI; Dhanasekaran DN; Tsang BK; Song YS
Oncogene; 2019 Nov; 38(45):7089-7105. PubMed ID: 31409904
[TBL] [Abstract][Full Text] [Related]
2. Hypoxia-induced ROS promotes mitochondrial fission and cisplatin chemosensitivity via HIF-1α/Mff regulation in head and neck squamous cell carcinoma.
Wu K; Mao YY; Chen Q; Zhang B; Zhang S; Wu HJ; Li Y
Cell Oncol (Dordr); 2021 Oct; 44(5):1167-1181. PubMed ID: 34460078
[TBL] [Abstract][Full Text] [Related]
3. Piceatannol enhances cisplatin sensitivity in ovarian cancer via modulation of p53, X-linked inhibitor of apoptosis protein (XIAP), and mitochondrial fission.
Farrand L; Byun S; Kim JY; Im-Aram A; Lee J; Lim S; Lee KW; Suh JY; Lee HJ; Tsang BK
J Biol Chem; 2013 Aug; 288(33):23740-50. PubMed ID: 23833193
[TBL] [Abstract][Full Text] [Related]
4. p53 is required for cisplatin-induced processing of the mitochondrial fusion protein L-Opa1 that is mediated by the mitochondrial metallopeptidase Oma1 in gynecologic cancers.
Kong B; Wang Q; Fung E; Xue K; Tsang BK
J Biol Chem; 2014 Sep; 289(39):27134-27145. PubMed ID: 25112877
[TBL] [Abstract][Full Text] [Related]
5. MicroRNA-148a-3p enhances cisplatin cytotoxicity in gastric cancer through mitochondrial fission induction and cyto-protective autophagy suppression.
Li B; Wang W; Li Z; Chen Z; Zhi X; Xu J; Li Q; Wang L; Huang X; Wang L; Wei S; Sun G; Zhang X; He Z; Zhang L; Zhang D; Xu H; El-Rifai W; Xu Z
Cancer Lett; 2017 Dec; 410():212-227. PubMed ID: 28965855
[TBL] [Abstract][Full Text] [Related]
6. Direct impact of cisplatin on mitochondria induces ROS production that dictates cell fate of ovarian cancer cells.
Kleih M; Böpple K; Dong M; Gaißler A; Heine S; Olayioye MA; Aulitzky WE; Essmann F
Cell Death Dis; 2019 Nov; 10(11):851. PubMed ID: 31699970
[TBL] [Abstract][Full Text] [Related]
7. ABT737 induces mitochondrial pathway apoptosis and mitophagy by regulating DRP1-dependent mitochondrial fission in human ovarian cancer cells.
Yu Y; Xu L; Qi L; Wang C; Xu N; Liu S; Li S; Tian H; Liu W; Xu Y; Li Z
Biomed Pharmacother; 2017 Dec; 96():22-29. PubMed ID: 28963947
[TBL] [Abstract][Full Text] [Related]
8. Akt-mediated cisplatin resistance in ovarian cancer: modulation of p53 action on caspase-dependent mitochondrial death pathway.
Yang X; Fraser M; Moll UM; Basak A; Tsang BK
Cancer Res; 2006 Mar; 66(6):3126-36. PubMed ID: 16540663
[TBL] [Abstract][Full Text] [Related]
9. Prohibitin 1 interacts with p53 in the regulation of mitochondrial dynamics and chemoresistance in gynecologic cancers.
Kong B; Han CY; Kim SI; Patten DA; Han Y; Carmona E; Shieh DB; Cheung AC; Mes-Masson AM; Harper ME; Song YS; Tsang BK
J Ovarian Res; 2022 Jun; 15(1):70. PubMed ID: 35668443
[TBL] [Abstract][Full Text] [Related]
10. CoCl
He Y; Gan X; Zhang L; Liu B; Zhu Z; Li T; Zhu J; Chen J; Yu H
Am J Physiol Cell Physiol; 2018 Sep; 315(3):C389-C397. PubMed ID: 29768044
[TBL] [Abstract][Full Text] [Related]
11. HIF Inactivation of p53 in Ovarian Cancer Can Be Reversed by Topotecan, Restoring Cisplatin and Paclitaxel Sensitivity.
Parmakhtiar B; Burger RA; Kim JH; Fruehauf JP
Mol Cancer Res; 2019 Aug; 17(8):1675-1686. PubMed ID: 31088908
[TBL] [Abstract][Full Text] [Related]
12. An improved quantitative approach for the assessment of mitochondrial fragmentation in chemoresistant ovarian cancer cells.
Farrand L; Kim JY; Im-Aram A; Suh JY; Lee HJ; Tsang BK
PLoS One; 2013; 8(9):e74008. PubMed ID: 24040144
[TBL] [Abstract][Full Text] [Related]
13. [Inhibition of mitochondrial Smac release by Akt in chemoresistant ovarian cancer cells].
Yang XK; Wang JD; Wang SY; Zhang YX
Zhonghua Zhong Liu Za Zhi; 2008 Apr; 30(4):259-62. PubMed ID: 18788627
[TBL] [Abstract][Full Text] [Related]
14. Akt promotes cisplatin resistance in human ovarian cancer cells through inhibition of p53 phosphorylation and nuclear function.
Fraser M; Bai T; Tsang BK
Int J Cancer; 2008 Feb; 122(3):534-46. PubMed ID: 17918180
[TBL] [Abstract][Full Text] [Related]
15. ABT737 enhances ovarian cancer cells sensitivity to cisplatin through regulation of mitochondrial fission via Sirt3 activation.
Hou L; Wang R; Wei H; Li S; Liu L; Lu X; Yu H; Liu Z
Life Sci; 2019 Sep; 232():116561. PubMed ID: 31247208
[TBL] [Abstract][Full Text] [Related]
16. Mitochondrial division inhibitor 1 reduces dynamin-related protein 1 and mitochondrial fission activity.
Manczak M; Kandimalla R; Yin X; Reddy PH
Hum Mol Genet; 2019 Jan; 28(2):177-199. PubMed ID: 30239719
[TBL] [Abstract][Full Text] [Related]
17. Mitochondrial dynamics regulates hypoxia-induced migration and antineoplastic activity of cisplatin in breast cancer cells.
Han XJ; Yang ZJ; Jiang LP; Wei YF; Liao MF; Qian Y; Li Y; Huang X; Wang JB; Xin HB; Wan YY
Int J Oncol; 2015 Feb; 46(2):691-700. PubMed ID: 25434519
[TBL] [Abstract][Full Text] [Related]
18. PGC1α regulates mitochondrial oxidative phosphorylation involved in cisplatin resistance in ovarian cancer cells via nucleo-mitochondrial transcriptional feedback.
Shen L; Zhou L; Xia M; Lin N; Ma J; Dong D; Sun L
Exp Cell Res; 2021 Jan; 398(1):112369. PubMed ID: 33220258
[TBL] [Abstract][Full Text] [Related]
19. PTEN-induced kinase 1-induced dynamin-related protein 1 Ser637 phosphorylation reduces mitochondrial fission and protects against intestinal ischemia reperfusion injury.
Qasim W; Li Y; Sun RM; Feng DC; Wang ZY; Liu DS; Yao JH; Tian XF
World J Gastroenterol; 2020 Apr; 26(15):1758-1774. PubMed ID: 32351292
[TBL] [Abstract][Full Text] [Related]
20. IRF-1 expression is induced by cisplatin in ovarian cancer cells and limits drug effectiveness.
Pavan S; Olivero M; Corà D; Di Renzo MF
Eur J Cancer; 2013 Mar; 49(4):964-73. PubMed ID: 23079474
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
